Bosutinib is a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL protein. It is approved by the FDA only in patients that have first been treated with another TKI. In that setting, it can be used to treat Chronic, Accelerated, and Blast Phase CML.
These side effects are common when patients start therapy but are usually mild to moderate. Most of these side effects improve over time but it is important to tell your doctor about any side effects you may be experiencing. Supportive medications can help with symptoms from these side effects and often, the TKI doses do not need to be modified.
Additional Information: https://medlineplus.gov/druginfo/meds/a613005.html